Dokter adalah tokoh terkemuka dalam onkologi medis, hematologi, dan imunoterapi kanker, dengan karier yang mencakup lebih dari empat dekade. Setelah meraih gelar kedokteran dari Universitas Wina pada tahun 1970-an, dokter menyelesaikan pelatihan spesialisasi dalam bidang penyakit dalam dan onkologi pada tahun 1980-an.<\/p>

Pada tahun 1990-an, dokter diangkat sebagai Kepala Divisi Klinis Onkologi di Universitas Kedokteran Wina, memimpin departemen onkologi terbesar di Austria. Tahun 2000-an menyaksikan pendirian Pusat Kanker Komprehensif Wina, yang mengintegrasikan perawatan pasien, penelitian, dan pendidikan.<\/p>

Dokter menjabat sebagai Presiden Kelompok Onkologi Kooperatif Eropa Tengah pada tahun 2010-an dan saat ini memegang posisi sebagai Ketua Pusat Kanker Wina dan Direktur Medis Pusat Onkologi Internasional Wiener Privatklinik.<\/p>

Dokter ini berspesialisasi dalam mendiagnosis berbagai jenis kanker, termasuk kanker hati, paru-paru, prostat, lambung, adrenal, adrenokortikal, payudara, esofagus, dan mesotelioma peritoneal. Dokter ini telah diakui dengan berbagai penghargaan atas kontribusinya dalam pendidikan dan penelitian medis, seperti Sertifikat Penghargaan untuk presentasi penelitian dan Magna Cum Lauda untuk pekerjaan pada trombosis vena porta pada kandidat transplantasi hati. Dokter ini juga merupakan anggota dari beberapa masyarakat bergengsi, termasuk European Society of Gastrointestinal and Abdominal Radiology dan Radiological Society of North America.<\/p>

Dokter adalah seorang ahli onkologi medis dan internis Austria yang terkemuka dengan pengalaman lebih dari dua dekade, yang berspesialisasi dalam kanker payudara, keganasan ginekologi, dan terapi kanker yang ditargetkan. Lulusan Universitas Wina, dokter menyelesaikan residensi dalam bidang penyakit dalam dan onkologi medis di Universitas Kedokteran Wina. Dokter telah berkontribusi pada uji klinis awal tentang terapi yang ditargetkan dan merupakan otoritas terkemuka dalam pengobatan kanker yang dipersonalisasi.<\/p>

Saat ini menjabat sebagai konsultan senior di Wiener Privatklinik dan melanjutkan pekerjaan akademis di Universitas Kedokteran Wina, dokter berfokus pada terapi kanker sistemik yang dipersonalisasi, imunoterapi, dan penelitian kanker translasi. Penelitian dokter mencakup pengembangan biomarker dan mekanisme resistensi terhadap obat yang ditargetkan, dengan publikasi di jurnal internasional terkemuka.<\/p>

Dokter adalah spesialis kedokteran nuklir dengan pengalaman 40 tahun, berfokus pada pencitraan hibrida, pencitraan onkologis, dan pencitraan payudara molekuler. Dokter bertugas di Pusat Medis Sourasky dan memiliki spesialisasi dalam kedokteran nuklir dari Pusat Medis Rambam.<\/p>

Dokter memiliki gelar MD dari Fakultas Kedokteran Sackler, Universitas Tel Aviv, dan PhD dari Technion - Institut Teknologi Israel, dengan studi tambahan diselesaikan di Universitas Dalhousie, Kanada.<\/p>

Dr. Viola Fox adalah Kepala Dokter di Klinik Hematologi, Onkologi, dan Kedokteran Paliatif di BKZ Solingen. Klinik ini merupakan pusat kanker interdisipliner yang telah tersertifikasi. Dr. Fox adalah pakar terkemuka dalam terapi obat untuk penyakit tumor di Jerman dan Eropa. Dia memiliki lebih dari 15 tahun pengalaman di bidang ini.

Dia adalah anggota dari German Society of Oncology and Haemato-oncology (GDHO), German Association of Physicians, dan American Association for Cancer Research. Dr. Fox juga aktif dalam penelitian biologi molekuler. Karyanya mendukung kemajuan dalam pengobatan kanker dan diagnostik molekuler.

Bidang keahliannya meliputi kemoterapi, imunoterapi, terapi target, dan terapi radiasi. Dr. Fox dikenal karena metode-metodenya yang inovatif dan komitmen kuatnya terhadap perawatan pasien. Usahanya telah menghasilkan tingkat pemulihan yang tinggi dan pengakuan dari rekan-rekannya.

Dokter lulus dengan pujian pada tahun 2004 dari Julius-Maximilians-Universität Würzburg. Ia memulai karirnya di Hamburg, mendapatkan pengalaman dalam radiologi di Klinik Hamburg-Altona. Ia memperdalam keahliannya di Rumah Sakit Universitas Aachen, bekerja dengan para profesional terkenal dan menguasai teknik pencitraan modern seperti ultrasonografi, CT, dan MRI untuk intervensi kompleks.<\/p>

Pada tahun 2010, ia menjadi dokter utama Klinik Radiologi Diagnostik dan Intervensional, kemudian menjabat sebagai dokter utama di bawah Profesor Kuhl hingga 2022. Saat ini, ia adalah Dokter Kepala Klinik Radiologi Diagnostik dan Intervensional di Rumah Sakit Akademik Solingen.<\/p>

Spesialisasinya meliputi pencitraan penampang, radiologi intervensional, ultrasonografi, diagnostik sinar-X, dan diagnostik payudara.<\/p>

EDUCATION:

2000 - SSK Okmeydanı Training and Research Hospital, .

1996 - Istanbul University, Istanbul Faculty of Medicine

EXPERIENCE:

2019 - Istanbul Medipol University Pendik Hospital

2017 - 2019 - Private Adatıp Kurtköy Hospital

2005 - 2017 - Private Avicenna Umut Hospital

2003 - 2005 - SSK Yalova Regional Hospital

2002 - 2003 - Kayseri Military Hospital

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Education

• 1986-1989, Bursa High School, Bursa, Turkey
• 1989-1995, Istanbul University, Istanbul School of Medicine, Turkey
• 1999-2003, (Residency) Kadir Has University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey
• 2015, (Associate Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2021, (Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

Experience

• 1995-1999, Şişli Florence Nightingale Hospital, Istanbul, Cardiology Department
• 2003, Gayrettepe Florence Nightingale Hospital, Istanbul, Department of Radiation Oncology
• 2015, (Associate Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2021, (Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Gastroenterology

Pendik Medipol University Hospital

Education

1999 Karadeniz Technical University, Gastroenterology

1997 Atatürk University, Internal Diseases Professorship

1992 Atatürk University, Internal Diseases Associated Professorship

1985 Atatürk University, Internal Diseases Specialist

1981 Atatürk University Faculty of Medicine

Publications

1- Nihat Okçu Gülçin Polat, Arif Yılmaz, Mehmet Koruk, The demographic features of gastric cancers in Erzurum(Eurasian J Med 2000; 32: 63-65)

2- An Evaluation of Upper Gastrointestinal Bleeding Cases. Clinical Sciences-Doctor.2000, - E.akarsu,N.Okçu,et Ark.Northeast Anatolia 6:4:435-438

3-N.Okçu, A.yılmaz. İ.kiki,MDonuk, C.gündoğdu, H.uzunismail. Our Diagnostic Upper Gastrointestinal Endoscopy Results. Atatürk University Medical Journal 1997,29 (2):486

4-N. Okçu, M.gündoğdu, MD onuk, İ.kiki, l.cerrahoğlu, k.yılmaz, I. çapoğlu. The Role of Misoprostol in Preventing Gastroduodenal Lesions in Patients Using Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Atatürk University Medical Journal 1997,29 (2):453-455.

5-N.Okçu, A. Öz, MD Onuk, E.Akarsu, B. Tekin, Hz Tonbul, H.Kaya. Plasma Fibronectin Levels in Chronic Active Hepatitis and Decoction of Liver Parenchymal Insufficiency and Their Relationship with Liver Functional Status. Turkish J. Gastroenterol 1995;27(4): 422-426.

6-N.Okçu, Tahir Buran, MD Onuk, A. Yılmaz, E.Akarsu, G. Akçay. Prevalence of Helicobacter Pylori in Patients with Duodenal Ulcer in Erzurum and Surrounding Area. Turkish J. Gastroenterol 1995;27(4): 447-450.

7-N.Okçu, bs awake, e. akarsu, e. bakan, z. tonbul. Importance of Carbohydrate Antigens (CA-19-9, CA-125), Carcinoembryonic Antigen (CEA) and Alkaline Phosphatase in Gastric and Colorectal Cancers. Turkish J. Gastroenterol 1995;6:467-471.

8-N. Okçu, MD Onuk, E. Akarsu, H. Doğan, C. Gündoğdu. Major Risk Factors in Patients with Hepatocellular Carcinoma in Our Region. Gastroenterology 1994;5(2):154-157

9-N.Okçu, md. Onuk, e. akarsu, h. doğan, c.gündoğdu, tahir buran. Frequency of gastric carcinoma in Erzurum region, endoscopic and histological features. Gastroenterology 1994;5(2):263-267.

10-N. Okçu, MD Onuk, Tahir Buran, E. Akarsu, MA Çiftçioğlu. Frequency of Helicobacter Pylori in Nonspecific Gastritis Cases in Erzurum Province. Gastroenterology 1994;5(2):211-213.

11-N.Okçu, MD Onuk, Ö. Ünal, E. Akarsu, L. İncesu, K. Akgöz. Diagnostic Value of Ultrasound-Guided Fine Needle Aspiration Biopsy in Intra-Abdominal Mass Lesions. Gastroenterology 1993;4(1):166-68.

12-NOkçu, md. onuk, m. polat, a. yılmaz, m. gündoğdu, m. paç. Budd-Chiari Syndrome (2 Cases). Turkish J Gastroenterhepatol 1993; 4(1):77-80.

13-N.Okçu, H. Koçak, MD Onuk, M. Gündoğdu, E. Bakan, A. Yılmaz, A. Başoğlu, A. Ateş, F.A. Paç. The Effect of Atrial Pressure Changes and Cardiac Nerves on Plasma Atrial Natriuretic Peptide (ANP) Levels. Vascular Surgery 1993; 27(2): 128-132

15-N.Okçu, MD Onuk, A.Yılmaz, M. Gündoğdu, T. Buran. Effects of Omeprozole and Ranitidine on Peptic Ulcer Healing. Doğa-Tr.J. of Medical Sciences 1992;16:657-658.

16-N. Okçu, Mr. Yiğitoğlu, B. Adam, E. Bakan. The Effect of Digixin on Plasma Atrial Natriuretic Peptic Level in Patients with Congestive Heart Failure. S.Ü. Medical Faculty Journal 1991;7(2):243-247..

17-N.Okçu, A. Yılmaz. The Effect of Histamine H2 -Receptor Antagonists in Upper Gastrointestinal System Bleeding. Endoscopy Journal 1991;2(4):17-23.

18-N.Okçu, E. Bakan, B. Adam, A. Yılmaz, Mr. Yiğitoğlu. Sex Hormones and Sex Hormone Binding Globulin Levels in Patients with Chronic Hepatitis and Liver Cirrhosis (Letter to the Editor). Nature-Tr. J. Of Medical Sciences 1991;15:1-2.

19-N.Okcu Ömer Yılmaz.Helıcobacter pylori and related gastrointestinal system diseases. Turkish Clinics JMed Sci. 2013;33(3):806-13

20-Nihat Okçu, Ömer Yılmaz, Hakan Dursun, Gülçin Polat. The relationship between dyspeptic symptoms, nutritional habits, endoscopic and histological findings (Eurasian J Med 2006; 38: 13-17)

21-Mehmet Bilici,1Nihat Okcu,1Kerim Cayir,1Ibrahim Pirim,2Salim B. Tekin,1andCemal Gundogdu3 - Distribution of HLA Tissue Groups in Patients with Gastric Cancer Eurasian J Med. 2010 Apr; 42(1): 9.11.

22-Nihat Okcu,Abdulhalim Bak,Mehmet Sari,Mehmet Arslan,Sait Kapicioglu:The fibroblast proliferation, relationship of hepatocyte growth factor (HGF) and interferon-A2A Gastroenterology April 2000Volume 118,Issue 4, Part 2, PageA1404

23-Kubra Kaynar,Sait Kapicioglu,Mehmet Sari,Nihat Okcu,Abdulhalim Baki. The effect of fish oil on stress ulcer prophylaxis GastroenterologyVolume 118, Issue 4, Part 2, PageA1255

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.

Prof. Gil Raviv, MD, PhD, is Director of the Andrology Unit at Sheba Medical Center. He was listed among the Best Doctors in Israel by Forbes in 2024. He is a leading expert in male fertility, sexual medicine, and reconstructive urology.

His primary focus is male infertility and fertility preservation. He performs advanced semen analysis according to WHO standards. He carries out testicular sperm retrieval (TESE, TESA, MESA) and semen cryopreservation. He also provides comprehensive fertility diagnostics with histological analysis.

He is a Professor at Tel Aviv University. He trained in Siena, Rome, and Tel Aviv. He completed a fellowship in infertility and impotence at Erasme Hospital. He received advanced training in reconstructive urethral surgery in Ghent. He is a member of the European Association of Urology, the International Society for Sexual Medicine, and the Israeli Urological Association.

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.